In this study, 221 breast cancer patients were found to have a decline in cognitive function following chemotherapy, and in breast cancer patients with disparate expression of HER2, there exists an obvious difference in EBPM and TBPM after chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.